Catching up in multiple myeloma, Pfizer taps ORIC for BCMA combo study

Pfizer has found a Phase II candidate that it believes would pair well with its experimental BCMA drug, and it’s infusing $25 million into the biotech behind the therapy.

As part of a new clinical development collaboration, Pfizer will test elranatamab, a BCMA CD3-targeted bispecific, in combination with ORIC Pharmaceuticals’...

Click to view original post